Optimizing Anticancer Treatment Management with a Functional Patient Derived Explants (PDE) Assay

Vered Bar, Ronen Viner, Adi Zundelevich, Sara Aharon, Seth Salpeter, Guy Neev

Company name-CURESPONSE * Website www.curesponse.com * CEO name-Guy Neev* * CATEGORY: Biotech * SESSIONS * • Liquid biopsy & Diagnostics:

Getting closer to transforming early detection and disease management • Evolving trends in cancer therapeutics Abstract Optimizing Anticancer Treatment Management with a Functional Patient Derived Explants (PDE) Assay Precision cancer therapy holds great promise for transforming patient outcomes through targeted disease management. Although genomic analysis has become a cornerstone of personalized cancer medicine, its impact on extending survival compared to traditional drug therapies has been limited. Furthermore, while identifying genomic mutations, these analyses often propose multiple therapeutic options without clarifying the most effective treatment strategy.

To enhance disease management in cancer care, we have developed the cResponse® platform. This innovative platform combines genomic and functional drug sensitivity testing to optimize treatment plans specifically for each patient. The cResponse® platform is capable of cultivating Personal Derived Explants (PDE) to accurately predict human responses to a wide spectrum of cancer therapies and oncology drug candidates, achieving an unprecedented 90% accuracy rate.

This groundbreaking technology demonstrates remarkable versatility across various cancer types and treatment modalities. Addressing a critical challenge in cancer treatment, where many drugs yield moderate to low response rates(20%-50%), necessitating a trial-and-error approach in matching drugs with patients, CURESPONSE offers a unique solution.

By assessing treatment effect against a patient's tissue, the platform enables personalized matching with the most effective drug from the outset. This personalized approach minimizes unnecessary side effects, reduces treatment delays, and optimizes healthcare resource allocation. Data analysis, derived from our clinical studies and laboratory results from hundreds of patients suggest significant actionable implications for cancer management, benefiting patients, oncologists, and healthcare systems alike.